Login to Your Account



CEO: A TESTAMENT TO THE TECHNOLOGY PLATFORM

Astrazeneca takes Bicycle to work in potential $1B multitarget collaboration

By Nuala Moran
Staff Writer

Thursday, December 1, 2016

LONDON – Bicycle Therapeutics Ltd. has convinced Astrazeneca plc of the attractions of its novel peptide platform, signing up the pharma in a potential $1 billion discovery and development collaboration in respiratory, cardiovascular and metabolic disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription